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Abstract  36 
Cardiovascular diseases (CVD) are the leading cause of death in women globally, with aging 37 
associated with progressive endothelial dysfunction and increased CVD risk. Natural menopause is 38 
characterised by raised non-fasting triacylglycerol (TAG) concentrations and impairment of 39 
vascular function compared with premenopausal women. However, the mechanisms underlying the 40 
increase in CVD risk after women have transitioned through the menopause are unclear. Dietary fat 41 
is an important modifiable risk factor in relation to both postprandial lipaemia and vascular 42 
reactivity. Meals rich in saturated and monounsaturated fatty acids are often associated with greater 43 
postprandial TAG responses compared with those containing n-6 polyunsaturated fatty acids, but 44 
studies comparing the effects of these fatty acids on vascular function during the postprandial phase 45 
are limited, particularly in postmenopausal women. A systematic search of the literature identified 46 
778 publications describing acute postprandial test meal studies including postmenopausal women. 47 
The impact of fat-rich meals on postprandial lipaemia was reported in 7 relevant studies, of which 48 
meal fat composition was compared in one study described by three papers. An additional study 49 
determined the impact of a high fat meal on vascular reactivity. Although there is moderately 50 
consistent evidence to suggest detrimental effects of high fat meals on postprandial lipaemia in 51 
postmenopausal women (compared with premenopausal women), there is insufficient evidence to 52 
establish the impact of meals of differing fat composition. Furthermore, there is no robust evidence 53 
to conclude the impact of meal fatty acids on vascular function or blood pressure. In conclusion, 54 
there is an urgent requirement for suitably powered robust randomised controlled trials to 55 
investigate the impact of meal fat composition on postprandial novel and established CVD risk 56 
markers in postmenopausal women, an understudied population at increased cardiometabolic risk.  57 
 58 
Introduction 59 
Cardiovascular diseases (CVD) which include coronary heart disease (myocardial infarction and 60 
angina), stroke and peripheral vascular disease (1) are a key contributor to the burden of disease 61 
globally (2). Over the past 50 years, the prevalence of CVD has fallen in Western populations, 62 
however, CVD are currently the major cause of death in women in the UK, accounting for 32% of 63 
all deaths (3). Furthermore, the prevalence of CVD is dramatically increasing in other areas, 64 
including Eastern Europe, Asia and the Indian subcontinent (4).  65 
The aetiology for CVD is multifactorial and includes several modifiable risk factors, such as 66 
cigarette smoking, a sedentary lifestyle, obesity, elevated blood pressure, dyslipidaemia, type 2 67 
diabetes mellitus, and non-modifiable factors, such as advancing ageing, sex, family history of heart 68 
disease and ethnicity (5; 6). Among the non-modifiable risk factors, ageing is associated with 69 
3 
 
progressive endothelial dysfunction (characterised by a loss of vascular wall homeostasis leading to 70 
a decrease in vascular reactivity and raised blood pressure) in both sexes, although it appears to 71 
occur earlier in men than women (7). The most prominent sex related difference in physiological 72 
ageing is the menopause (cessation of menstruation) in women, which usually occurs between the 73 
ages of 45 and 55 y, with 51 y being the average age of menopause in the UK (8). This natural part 74 
of aging in women contributes a significant cardiovascular milestone in terms of both physiology 75 
and pathology since oestrogen deficiency is known to impair lipid metabolism and endothelial 76 
function, and the menopause is a recognised risk factor for CVD (9). It has further been shown by 77 
Schouw et al. (10) that for each year of delay in the age of onset of the natural menopause, CVD risk 78 
falls by 2%.  79 
 80 
Postprandial lipaemia  81 
Kolovou et al. defined postprandial lipaemia as a complex syndrome characterised by non-fasting 82 
hypertriacylglycerolaemia and its augmentation is associated with increased risk of cardiovascular 83 
events (11). Following a fat containing meal, there is a transient rise in circulating triacylglycerol 84 
(TAG) rich lipoproteins (TRL), such as chylomicrons (CM) and very low density lipoprotein 85 
(VLDL). After entering the circulation, the CM TAG is hydrolysed into non-esterified fatty acids 86 
(NEFA) by lipoprotein lipase (LPL) forming cholesterol ester rich CM remnants, which are cleared 87 
by the liver by receptor-mediated uptake.  VLDL follows a similar route of metabolism in the 88 
circulation as CM particles, but VLDL are hydrolysed at a slower rate, as the larger CM are 89 
preferential substrate for LPL. VLDL TAG depletion produce smaller VLDL (intermediate density 90 
lipoprotein or VLDL remnants), ultimately a proportion of which will be metabolised to low density 91 
lipoprotein (LDL). LDL particles are cleared from the bloodstream via the hepatic LDL receptor 92 
using apoB-100 as a ligand. During the postprandial period, there is an accumulation of TRL in the 93 
circulation due to competition between intestinal and hepatic TRL for the same lipolytic and 94 
receptor mediated uptake (12). A delayed clearance of TRLs in the circulation enhances the 95 
accumulation of TRL particles carrying acceptor sites for the cholesteryl ester transfer protein 96 
(CETP) which transfers TAG from TRLs (CM and VLDL) and exchanges it with cholesteryl esters 97 
from high density lipoprotein (HDL) and LDL. Remodelling of the lipid content of the LDL and 98 
HDL particles make them suitable substrates for LPL and hepatic lipase, leading to the formation of 99 
smaller denser LDL (LDL3) and HDL (HDL3) particles 
(13). HDL3 is rapidly removed from the 100 
circulation decreasing circulating HDL cholesterol (HDL-C) concentrations, which is one proposed 101 
mechanism for the inverse association between exaggerated postprandial lipaemia and CVD risk 102 
(14). Another possible mechanism is that LDL3 has a lower binding affinity to the LDL-receptor, 103 
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reducing their rate of clearance from the circulation and enabling them to infiltrate the arterial wall 104 
(13).     105 
Since atherosclerosis is now also considered to be a postprandial phenomenon, three large 106 
prospective cohort studies aimed to determine the link between cardiovascular events and non-107 
fasting TAG (15; 16; 17). In the Norwegian Counties Study,  hazard ratios of 1.2 and 1.03 for deaths 108 
from CVD per 1 mmol/l increase in non-fasting TAG were reported in women and men, 109 
respectively, after 27 years of follow up in a total of 86,261 participants (17).  Furthermore, the 110 
Copenhagen City Heart Study that followed 7581 women and 6391 men for 31 years showed that 111 
relative to women with non-fasting TAG of <1 mmol/L, hazard ratios for myocardial infarction 112 
ranged from 1.5 for women with TAG between 1.0-1.99 mmol/L rising to 4.2 for those with TAG 113 
≥5 mmol/L(16). However, the corresponding hazard ratios for men were 1.3 and 2.1, respectively. In 114 
the Women’s Health Study, fasting (n=20,118) and non-fasting (n=6391) TAG predicted 115 
cardiovascular events after 11.4 years of follow up after adjusting for age, blood pressure, smoking 116 
status and hormone therapy. The authors also reported that the strongest association between 117 
cardiovascular events and non-fasting TAG occurred 2-4 h after the last meal, with the association 118 
declining as the fasting time increased (15). These studies have demonstrated the greater importance 119 
of non-fasting than fasting TAG concentrations as a predictor of CVD risk in women than men.  120 
The relationship between postprandial lipaemia and CVD according to menopausal status is 121 
a topic of current interest. The impact of menopausal status on the variability of the postprandial 122 
lipaemic responses have been reported in a number of studies (18; 19; 20; 21) (Supplemental material 1). 123 
In general, premenopausal women have lower postprandial triacylglycerol (TAG) responses than 124 
men (22; 23; 24; 25), which is in contrast to the higher reported responses observed in postmenopausal 125 
women compared with men of a similar age (26). In response to a single oral vitamin A fat loading 126 
test, van Beek et al. (18) investigated whether a natural menopause was associated with reduced 127 
protection from exaggerated postprandial lipaemia. Higher concentrations of postprandial plasma 128 
TAG and retinyl palmitate (an indirect marker of CM) were observed in postmenopausal women 129 
compared with premenopausal women of similar age, BMI, daily energy and fat intake, APOE 130 
genotype, LPL activity, and HDL-C concentration, even after adjusting for the confounding effect 131 
of fasting TAG. Relative to premenopausal women, Masding et al.(20), Schoppen et al. (19) and 132 
Jackson et al.(21) also reported significantly higher postprandial TAG responses after single and 133 
sequential fat-rich test meals in healthy postmenopausal women. Although raised LDL cholesterol 134 
(LDL-C) is an established risk factor for CVD, large prospective studies have shown non-fasting 135 
TAG to be a better predictor of CVD risk in women than fasting LDL-C (27; 28; 29). Post-hoc analysis 136 
of the The Dietary Studies: Reading Unilever Postprandial Trials (DISRUPT) menopausal groups 137 
according to age also revealed a greater increase in non-fasting TAG than fasting LDL-C during the 138 
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late premenopausal period suggesting that age and the menopause have a differential impact on 139 
these two lipid CVD risk biomarkers (21).    140 
A major biochemical change that occurs in women after the menopause is a reduction in the 141 
secretion of endogenous oestrogen and progesterone (30). These hormones not only play a major role 142 
in sexual physiology, but are also involved in various physiological processes associated with the 143 
vasculature and lipid metabolism. A reduction in oestrogen following the menopause has been 144 
shown to have a detrimental impact on lipoprotein metabolism, vascular reactivity and blood 145 
pressure (Figure 1). For example, there is much evidence to suggest that oestrogen (endogenous and 146 
exogenous) lowers fasting plasma concentrations of total and LDL-C, lipoprotein (a) and 147 
apolipoprotein B, whilst elevating HDL-C and apolipoproteins AI and AII (31; 32; 33). The impact of 148 
oestradiol (the predominant type of oestrogen) on lipid metabolism is reported to contribute 25% of 149 
its protective effects for fasting lipid profile (34) . One possible mechanism to explain this effect, that 150 
was identified in in vitro animal studies, was an increase in the number of high affinity LDL 151 
receptors on liver cell membranes that enhance LDL uptake by the liver (33). Exaggerated 152 
postprandial lipaemia is observed after the menopause (18) but the administration of even short term 153 
(two to six weeks) oestradiol therapy reduces the menopause-related rise in postprandial TAG in 154 
postmenopausal women (35; 36). These findings indicate that 17β-estradiol may accelerate the 155 
postprandial clearance of TRL and have a beneficial effect on postprandial lipaemia.     156 
 157 
Vascular function and blood pressure  158 
Vascular function is a measure of cardiovascular health. The components of impaired vascular 159 
function, including hypertension (37; 38), arterial stiffness (39) and impaired endothelial dependent 160 
vasodilation (endothelial dysfunction) (40; 41), are all associated with cardiovascular mortality. In a 161 
healthy blood vessel, the endothelium, which is comprised of a monolayer of endothelial cells that 162 
lines the blood vessel walls, regulates vascular wall homeostasis by immediately responding to 163 
blood-borne and locally produced stimuli to regulate blood flow, blood pressure and vascular tone. 164 
It does so by maintaining a precise balance between the release of endothelium-derived vasodilators 165 
(such as nitric oxide (NO)), and vasoconstrictors (such as endothelin-I), which actively regulates 166 
vascular permeability to plasma constituents, platelets and leukocyte adhesion molecules (42) as well 167 
as aggregation and thrombosis (43). However, when the production or bioavailability of NO is 168 
reduced, the resulting imbalance of these vasoactive substances disrupts vascular homeostasis. This 169 
‘endothelial dysfunction’ is characterised by vasoconstriction, increased expression of adhesion 170 
molecules and pro-inflammatory cytokines, platelet activation and increased oxidative stress (44), 171 
and is becoming increasingly recognised as an important step for the initiation of coronary 172 
atherosclerosis (45) and CVD risk in postmenopausal women (46). There is supporting evidence of 173 
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impaired endothelial function after the menopause, which has been associated with a lack of 174 
endogenous oestrogen (7; 47). 175 
There are a number of non-invasive methods which are used to evaluate endothelial function 176 
(48). Flow-mediated dilatation (FMD) is the gold standard technique that uses ultrasound to assess 177 
endothelium-dependent vasodilation in the conduit arteries in the peripheral circulation and is used 178 
as a surrogate measure of NO production (49). It is now recognised as a screening tool to assess 179 
future CVD risk (40; 46; 50; 51). Rossi et al. reported that postmenopausal women in the lowest tertile of 180 
% FMD response (reflective of impaired vascular reactivity) had the greatest relative risk of 181 
cardiovascular events. Furthermore, it has been shown that endothelial function is impaired across 182 
the stages of the menopause transition in healthy women with the highest % FMD response reported 183 
in premenopausal women, with a progressive decline in perimenopausal and postmenopausal 184 
women, respectively (52). This suggests the perimenopausal stage (the transition towards the 185 
menopause where oestrogen production starts to fall) is a crucial turning point in women where 186 
changes in CVD risk commence.  187 
Majmudar et al. (53) revealed that menopausal status is associated with reduced NO activity, 188 
which is restored with oestrogen replacement therapy and may be an important mechanism 189 
facilitating the detrimental effect of the menopause on CVD risk and mortality. Another study that 190 
acutely administered oestrogen (17β-oestradiol) to postmenopausal women demonstrated protective 191 
effects on forearm microvascular responses to both endothelium-dependent (acetylcholine) and -192 
independent vasodilation (sodium nitroprusside) via improvements in NO activity (54). Impaired 193 
blood flow in the microcirculation has been proposed to be an indicator of initial endothelial 194 
damage in subjects at risk of CVD (55). Furthermore, it has been repeatedly shown that 17β-195 
oestradiol stimulates the production of vasodilatory prostaglandins, such as prostacyclin (PGI2) 
(56; 196 
57). These vascular effects are believed to be partly responsible for the long-term benefit of 197 
oestrogen therapy on cardiovascular risk in postmenopausal women. However, findings from the 198 
Women’s Health Initiative study have questioned the benefits of oestrogen therapy, reporting that 199 
oestrogen therapy did not protect against myocardial infarction or coronary death after a short (6.8 200 
y) or longer-term (18 y) follow-up relative to a placebo, although the findings did show a lower risk 201 
of coronary heart disease among the younger postmenopausal women (50 to 59 y) (58; 59)  (59). More 202 
recently, a systematic review involving 43,637 women reported the number of cardiovascular 203 
events to increase following the long-term (>1 y) use of oestrogen therapy (60). In contrast, there is 204 
much evidence to suggest that oestrogens (endogenous and exogenous) have several cardio-205 
protective effects (Figure 1) (32; 61; 62). These include reductions in plasma markers of endothelial 206 
activation (E-selectin) and increased fibrinolytic activity (increased factor VII; reduced fibrinogen, 207 
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plasminogen activator inhibitor type 1 and tissue plasminogen activator) (32; 63). However, increased 208 
markers of inflammation (C-reactive protein) and hypercoagulability have also been reported (32; 61). 209 
Hypertension (high blood pressure) is one of the main age-related disorders in 210 
postmenopausal women (64; 65), which has been identified as a leading risk factor for myocardial 211 
infarction and stroke in women (66). The renin-angiotensin system (RAS) is a hormonal cascade, 212 
which plays a key role in the regulation of fluid and electrolyte balance, and arterial blood pressure. 213 
Upon activation of the RAS cascade, angiotensin II is produced in the liver by angiotensin-214 
converting enzyme (ACE) following conversion of angiotensin I to angiotensin II (67). Angiotensin 215 
II is a potent vasoconstrictor which degrades bradykinin (a vasodilator) causing arterioles to 216 
constrict, resulting in increased blood pressure (68). It is well documented in the literature that 217 
oestrogen acts on RAS at different points of the cascade including the inhibition of ACE activity. In 218 
vitro and in vivo animal studies have also demonstrated the potential effects of oestrogen on the 219 
endothelial-dependent vasodilator response to acetylcholine due to oestrogen induced sensitisation 220 
measured in coronary and uterine arteries(69; 70; 71). Loss of oestrogen-dependent cardiovascular 221 
protection induces endothelial dysfunction, and may also be involved in the activation of the RAS 222 
cascade. Evidence from both clinical and animal studies have shown an inverse association between 223 
oestrogen and the activation of RAS (72; 73; 74; 75). This has been proposed to occur due to oestrogen 224 
induced downregulation of angiotensin receptor I expression leading to an augmented level of 225 
angiotensin II (73) (which is a major component of the RAS system) and has several harmful effects 226 
on the vascular wall including vasoconstriction, vascular smooth muscle cell proliferation, reactive 227 
oxygen species (ROS) generation, and endothelial cell apoptosis (76; 77; 78). Oestrogen deficiency has 228 
also been reported to lead to an upregulation of ACE activity causing an accumulation of 229 
angiotensin II (79).  230 
 231 
Impact of meal fat composition on postprandial lipaemia and vascular function 232 
Diet is one of the most important modifiable risk factors in relation to CVD (80). As a strategy to 233 
reduce the incidence of CVD, public health policy makers recommend that intakes of dietary 234 
saturated fatty acids (SFA) are reduced to <10% total energy in the UK (81). Substituting SFA with 235 
unsaturated fatty acids may provide additional benefits in relation to CVD risk factors, including 236 
reductions in the fasting lipid profile and improvements in endothelial function. A systematic 237 
review proposed that lowering dietary SFA intake by modifying dietary fat composition rather than 238 
reduction in total fat intake, may reduce cardiovascular events by 14% (82). Since individuals spend 239 
a large proportion of the day in the fed (postprandial) state, modifications to the fatty acid 240 
composition of our meals that are repeated on a daily basis may have a significant impact on 241 
postprandial lipaemia and vascular health, which over time could affect CVD risk.    242 
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The chronic effects of substitution of SFA with polyunsaturated fat (PUFA) on fasting lipid 243 
levels have been extensively studied (83), however, the acute affects are less well known. One 244 
systematic review and meta-analysis of RCT compared the effects of oral fat tolerance tests with 245 
differing fatty acid compositions on postprandial TAG responses in men and women (84). Relative to 246 
a single SFA-rich meal challenge, a PUFA-rich meal significantly reduced the postprandial 247 
lipaemic response over 8 h, whereas a trend for a reduced response was identified following a 248 
monounsaturated (MUFA) rich meal challenge. However, differences were not evident at 4 h 249 
suggesting that a longer follow-up time after the test meal (i.e. 8 h) is required to observe the acute 250 
effects of meal fat composition on postprandial lipaemia. Of the 18 studies included in the review 251 
by Monfort-Pires et al. (84) none of the studies included postmenopausal women which reflects the 252 
paucity of postprandial data in this population subgroup.     253 
With regards to vascular function, West and colleagues (85) reported that consumption of a 254 
single high fat meal (50-105 g of fat) can impair postprandial FMD by 45% to 80% with 255 
observations of impaired FMD within 2 to 5 h after a high fat meal (86; 87; 88; 89).  Prolonged 256 
postprandial lipaemia is known to induce endothelial dysfunction by promoting the formation of 257 
free radicals by accelerating the rate of β-oxidation of free fatty acids (e.g. superoxide radicals). 258 
Increased production of ROS or free radicals reduce the amount of bioactive NO by chemical 259 
inactivation to form toxic peroxynitrite (90). In addition, it has been shown that persisting oxidative 260 
stress will render endothelial nitric oxide synthase dysfunctional, markedly reducing NO production 261 
(91).  Indeed, high concentrations of TRLs during the postprandial state enhance inflammation by 262 
inducing the secretion of pro-inflammatory cytokines (92) and expression of soluble cell adhesion 263 
molecules (93). 264 
Reviews by Hall (94) and Vafeiadou et al. (95) stated that the acute effects of dietary fats on 265 
vascular function is less researched. The authors concluded that high fat meals have a detrimental 266 
effect on postprandial vascular function and that there is limited and inconclusive evidence for the 267 
comparative effects of test meals rich in MUFA or n-6 PUFA with SFA. Of note, the data derived 268 
from these reviews were mainly from studies where the effects of a single high fat meal on 269 
postprandial vascular function in different subject groups were determined; however, none of the 270 
studies identified in these reviews included only postmenopausal women only.  271 
Therefore, we aimed to systematically review and critically evaluate the existing evidence 272 
from acute studies comparing meals rich in SFA, MUFA and n-6 PUFA on postprandial lipaemia, 273 
vascular reactivity, blood pressure and biomarkers of vascular function and inflammation in 274 
postmenopausal women. It is very timely to focus on postmenopausal women since they represent 275 
an understudied group within the population at increased CVD risk.     276 
 277 
9 
 
Subjects and methods 278 
A systematic approach was used to identify all relevant published literature according to the method 279 
used by Vafeiadou et al. (95). The PubMed (http://www.ncbi. nlm.nih.gov/pubmed/) database was 280 
used to perform the literature search, which included all studies published in English until October 281 
2016. A protocol that included search terms to conduct the literature search was prepared by two 282 
authors (KMR and MW) and then agreed by all authors. Three categories of search terms were 283 
identified: i) study group search term (postmenopausal or post-menopausal or post menopause or 284 
menopause or menopausal); ii) exposure search terms (which included descriptors of SFA, MUFA 285 
and n-6 PUFA, and relevant food sources, e.g. butter, safflower oil and olive oil); iii) outcomes 286 
(which included descriptors of vascular function, blood pressure, biomarkers of vascular function 287 
and inflammation, and plasma lipids) (Supplementary Information). The Medical Subject Heading 288 
Browser (http://www.nlm.nih.gov/mesh/MBrowser.html) was used to identify relevant exposures 289 
and outcomes. Additional studies (n=2) were identified through hand searching of original articles 290 
found using the PubMed search. The titles and abstracts of every paper was assessed for relevance 291 
at the initial stage by one author (KMR) and any uncertainties were discussed with other members 292 
of the review team until a consensus was reached. This review was restricted to epidemiological 293 
studies (cross-sectional, case-control and cohort) and RCT in postmenopausal women with respect 294 
to test meals rich in SFA, MUFA and/or n-6 PUFA. Only published peer-reviewed literature was 295 
considered (i.e. ‘grey’ literature, such as dissertations, conference proceedings, reports, letters to 296 
editors and other non-peer-reviewed research were excluded). Although Hall (94) and Vafeiadou et 297 
al. (95) previously reviewed the chronic and acute studies on vascular function, they did not 298 
specifically address the acute effects in postmenopausal women. In this present review, we only 299 
considered acute studies as our objectives were to determine the impact of meal fatty acids on non-300 
fasting TAG responses, vascular function and blood pressure as important CVD risk factor in 301 
postmenopausal women. Figure 2 presents a summary of the literature search and reasons for 302 
exclusion of the studies.       303 
 304 
Results and Discussion  305 
This systematic search identified 778 publications in total. Of these, there were nine relevant 306 
articles describing seven independent studies in postmenopausal women that examined the acute 307 
effects of meals enriched in SFA and/or MUFA and/or n-6 PUFA on postprandial lipaemia (96; 97; 98; 308 
99; 100; 101; 102; 103; 104) . One of these studies also determined the impact of a single fat containing meal 309 
with a low PUFA:SFA ratio on vascular function (101) (Table 1). No studies were identified that 310 
reported the acute impact of meal fatty acids on postprandial blood pressure, or biomarkers of 311 
vascular function and inflammation in postmenopausal women. Only one single-blind RCT 312 
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compared the effects of meal fat composition on postprandial lipaemia using a sequential meal 313 
protocol, the results of which were presented in three publications (97; 98; 100). As opposed to a single 314 
meal protocol, the use of a multiple meal design by the researchers is considered superior because it 315 
more closely mimics the eating pattern of free-living individuals, particularly in Westernised 316 
societies, and provokes a sustained lipaemic response. Five publications described cross-sectional 317 
epidemiological studies, which were single arm studies that did not have comparator meals and 318 
whose fatty acid compositions varied (96; 101; 102; 103; 104). Among these postprandial studies with 319 
blood samples collected between 6 to 10 hours after the test meal, two studies (96; 102) used a 320 
sequential two meal protocol, whereas the other three studies (101; 103; 104) incorporated a single meal 321 
approach. In addition, one case-control study was identified that considered the responses of 322 
normolipaemic, hypercholesterolaemic and mixed hyperlipidaemic postmenopausal women to a 323 
single high fat meal (99).   324 
Data on these human studies will be presented in two sections that address the effects of 325 
total fat or fatty acid composition on i) postprandial lipaemia and ii) postprandial vascular function 326 
in postmenopausal women.  327 
 328 
Acute effects of meal fat composition on postprandial lipaemia  329 
The five cross-sectional studies, investigating both single and sequential meals, provided consistent 330 
evidence that fat-rich loads, irrespective of fatty acid composition, augment postprandial lipaemia in 331 
postmenopausal women, with an increase in TAG being observed in all five studies during the 332 
postprandial period relative to baseline (96; 101; 102; 103; 104) (Table 1). Furthermore, Pirro et al. (99) 333 
investigated the changes in postprandial TAG concentrations after a standardised oral fat load (65g 334 
of fat) at baseline, 4, 6 and 8 h in postmenopausal women with hypercholesterolemia and mixed 335 
hyperlipidaemia and compared them with a control group of normolipidaemic postmenopausal 336 
women. A significantly greater postprandial TAG response was found in the mixed hyperlipidaemic 337 
women than in the hypercholesterolaemic and normolipidaemic women which may reflect their 338 
higher baseline TAG concentrations. As expected, other factors involved in lipid metabolism, 339 
including increases in apo B-48 (102), glucose (103), and insulin (103) as well as reductions in HDL (99; 340 
103; 104), glutathione (101) and NEFA (103) were also observed postprandially compared with fasting 341 
values. However, comparison of the findings from the different studies are challenging due to 342 
differences in the nature of the fats and oils used in the test meal, the amount and composition of 343 
fat, and postprandial follow up times, as well as the use of both single and sequential test meal 344 
protocols. They are also limited in their cross-sectional design in that the lack of comparator meals 345 
prevents any conclusions from being made regarding the impact of meal fat composition on 346 
postprandial lipaemia. Among all nine articles (seven independent studies) reported in Table 1, only 347 
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one study that was described in three publications compared the postprandial lipaemic responses to 348 
test meals containing oils rich in SFA (palm oil), MUFA (olive oil), n-6 PUFA (safflower oil) and a 349 
mixture of n-6 PUFA and n-3 PUFA (safflower and fish oils) (97; 98; 100). In this study, 10 350 
postmenopausal women ingested a high fat breakfast containing 40 g of the assigned test fat 351 
followed by a low fat, high carbohydrate lunch (5.4 g total fat) given 5 h later. The authors observed 352 
significantly higher levels of plasma NEFA and lower insulin sensitivity following the SFA meal 353 
compared with the other test oils. During the postprandial state it has been shown that up to 50% of 354 
the liberated NEFA is dietary-derived CM-TAG due to the action of LPL upon TAG to release 355 
NEFA (100). Although Robertson et al. (100) did not determine the specific fatty acid composition of 356 
the circulating NEFA after consumption of the meals, a similar study reported the postprandial 357 
change in the plasma NEFA profile to represent the fatty acid composition of the test meals (105). 358 
Based on the same sequential meal study, Jackson et al. further examined the postprandial TAG and 359 
apo B-48 (the apolipoprotein specifically associated with CM) responses, including the responses in 360 
three distinct TRL subfractions, and reported significant differences in the apo B-48 time course 361 
profiles between the four different test oils (98). In particular, the MUFA meal resulted in the 362 
formation of a greater number of both large (Svedberg flotation rate (Sf>400 fraction) and 363 
moderately (Sf 60-400 fraction) sized apo B-48 particles compared with the other three study meals. 364 
The findings from this study suggested that olive oil may enhance CM formation and Jackson et al. 365 
(97) hypothesised that MUFA may modify the activity or expression of intestinal microsomal TAG 366 
transfer protein, which is involved with TRL lipoprotein assembly.  367 
 368 
Acute effects of meal fat composition on vascular function 369 
Only one study has also examined the acute impact of total fat and/or SFA and/or MUFA and/or n-6 370 
PUFA on vascular reactivity in postmenopausal women. A significant decrease in the %FMD 371 
response at 2 h (2.3 ± 2.6%) compared with baseline (7.7 ± 2.8%, p < 0.05) was observed in healthy 372 
postmenopausal women after a 65 g oral fat load with a PUFA:SFA ratio of 0.06 (101) (Table 1). 373 
Since a comparator meal of a different fatty acid composition was not included in this study, 374 
conclusions regarding the impact of fatty acid composition on vascular function in postmenopausal 375 
women cannot be determined.  376 
 377 
Summary  378 
A systematic approach was used to review the literature on the impact of meal fat composition 379 
(SFA, MUFA and n-6 PUFA) on postprandial lipaemia, blood pressure, vascular function and 380 
biomarkers of vascular function and inflammation in postmenopausal women. However, there is at 381 
present, an extremely limited number of RCT that have investigated the impact of meal fatty acid 382 
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composition on measures of postprandial lipaemia and vascular function in this population sub-383 
group. Furthermore, differences in study designs (such as the absence of a comparator test meal, 384 
and differences in meal fat composition, study duration and outcome measures) prevent any firm 385 
conclusions being drawn from this literature review. 386 
 387 
Conclusions  388 
In conclusion, there is an urgent requirement for suitably powered RCT to investigate the effects of 389 
meal fat composition on postprandial lipaemia and vascular function in postmenopausal women. 390 
With the increased prevalence of non-communicable diseases in women, especially after the 391 
menopause, future studies should consider both healthy postmenopausal women and those at 392 
increased cardiometabolic risk using well-standardised measures of vascular function. Since non-393 
fasting TAG is an important CVD risk factor for women, it is essential to use robust test meal 394 
protocols that are more reflective of habitual eating patterns to gain a greater understanding of the 395 
day-long postprandial handling of different dietary fats. 396 
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Table 1 Acute test meal studies investigating the effects of meal fat content and composition on postprandial lipaemia and vascular 
function in postmenopausal women 
    
Reference Subject group, 
age (mean) and n 
Study 
design 
Meal 
type  
Amount of 
fat (% meal 
fat if 
available) 
Fatty acid  composition Time of 
postprandial 
data 
Postprandial 
measurements 
(plasma/serum) 
Significant outcomes compared to 
baseline, unless otherwise stated 
Postprandial lipaemia 
Westerveld et 
al. (1996)(104)  
59 y n 16 
normolipidaemic 
 
 
 
Cross 
sectional*  
 
Single  
 
 
 
50 g (40%) PUFA: SFA 0.06 8 h TAG, HDL-C 
and HDL-Apo 
A-1  
 
 
 
↓HDL-C at 3 to 8 h (p<0.05),  
↓HDL-Apo A-1 at 3 and 6 h (p<0.05)  
↑TAG at 8 h (p<0.05) 
 
 
 
Pirro et al. 
(2001)(99)  
57 y n 17 
normolipaemic, 
54 y n 17 
hypercholesterola
emia and 55 y n 
16 mixed 
hyperlipaemia  
 
Case 
control  
Single  
 
 
 
 
 
 
 
65 g (83%) PUFA: SFA 0.06 8 h TC, TAG, 
HDL-C, HDL2 
HDL3, LDL, 
LDL particle 
size, and Lp(a) 
↑TAG at 4,6 and 8 h, ↓HDL-C at 6 h 
and ↓Lp(a) at 4 and 6 h in 
normolipaemic PoM (p<0.05) 
 
↑TAG at 4, 6 and 8 h, ↓HDL-C at 4 
and 6 h, ↓HDL2 at 4 h and ↓Lp(a) at 4 
h in hypercholesterolaemia PoM 
(p<0.05) 
 
↑TAG at 4, 6 and 8 h, ↓LDL size at 4 
and 6 h, ↓HDL-C at 4, 6 and 8 h, 
↓HDL2 at 6 h and ↓Lp(a) at 4 and 6 h 
in mixed hyperlipaemia PoM (p<0.05)  
Silva et al. 
(2005)(102)  
52-76 y (62 y)  
n 17 
 
 
 
 
 
Cross 
sectional* 
 
Seque
ntial  
Breakfast:  
30 g (46%) 
Lunch: 
44 g (52%) 
Breakfast (27 %E SFA, 12 %E 
MUFA, 5 %E PUFA and 2 %E 
Trans) 
Lunch (27 %E SFA, 18 %E 
MUFA, 5 %E PUFA and 2 %E 
Trans) 
10 h TAG, and apo 
B-48 
 
 
 
 
 
↑TAG at 210 min after breakfast and 
60 min after lunch 
↑Apo B-48 at 150 min after breakfast 
and 60 min after lunch 
Alssema et al. 
(2008)(96)  
60.1 y n 76 
 
 
 
 
 
Cross 
sectional*  
 
 
 
 
Seque
ntial  
Both breakfast 
and lunch 
compositions: 
 
Fat rich meal:  
50 g fat,  
No information 8 h TAG, HDL-C 
and CETP 
 
↑TAG at 8 h (p<0.05), ↓HDL-C at 8 h 
(p<0.05) in fat rich meal  
↑TAG at 8 h (p<0.05), ↓HDL-C at 8 h 
and ↑CETP in CHO rich meal 
(p<0.05) 
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* No comparator group.  
 
 
 56 g CHO,  
28 g protein 
 
CHO rich 
meal:  
4 g fat,  
162 g CHO, 
22 g protein 
 
 
Wassef et al. 
(2012)(103)  
58 y (45-74 y)   
n 19 obese PoM 
Cross 
sectional* 
Single 13C-labeled 
breakfast 80 g 
fat (68%) + 
0.017 g     
13C-triolein/g 
fat 
25 %E SFA, 26 %E MUFA,  
10 %E PUFA and 6 %E other 
sources 
6 h TAG, glucose, 
NEFA and 
Insulin 
↑TAG after meal 
↓NEFA between 1 to 2 h 
↑Glucose at 1 h 
↑Insulin AUC at 1 h  
Robertson et 
al. (2002)(100)  
 
Jackson et al. 
(2002a)(98)  
 
Jackson et al. 
(2002b)(97)  
50-63 y (56 y)  
n 10 
 
 
 
 
 
 
 
 
Single-
blind 
randomised 
crossover  
 
 
 
 
 
 
 
 
 
Seque
ntial  
Breakfast:  
41 g† 
Lunch:  
6 g  
High SFA (g/100 g):  
10 g n-6 PUFA, 0 g n-3 PUFA, 
40 g MUFA and 50 g SFA 
 
High MUFA (g/100 g):  
11 g n-6 PUFA, 0 g n-3 PUFA, 
72 g MUFA and 17 g SFA 
 
High n-6 PUFA (g/100 g):  
74 g n-6PUFA, 0 g n-3 PUFA, 
15 g MUFA and 11 g SFA 
 
High n-3/n-6 PUFA (g/100 g):  
39 g n-6 PUFA, 22 g n-3 
PUFA, 22 g MUFA and 19 g 
SFA 
8 h Glucose,  
NEFA and 
insulin 
 
 
 
 
 
 
 
TAG and  
apo B-48 
 
 
TAG, apo B-48, 
and in three 
TAG-rich 
lipoprotein 
subfractions   
 
High insulin response: SFA > n-6 
PUFA > n-3 PUFA > MUFA 
(p<0.006) 
Glucose: No significant effect  
↑NEFA at 5 h following high SFA 
breakfast and 30 min after low-fat 
high-CHO meal  
↓insulin sensitivity: SFA < n-6 PUFA 
< n-3 PUFA < MUFA 
 
↑apo B-48 in MUFA than SFA, n-6 
PUFA and n-3/n-6 PUFA meals 
(p≤0.009) 
 
apo B-48 IAUC in the Sf 60-400 
fraction greater than in the Sf> 400 
fraction for the SFA, n-6 PUFA and 
MUFA meals (p<0.04) 
↑apo B-48 IAUC in the Sf> 400 
fraction in MUFA than SFA, n-6 
PUFA and n-3/n-6 PUFA meals 
(p<0.02) 
Postprandial lipaemia and vascular function  
Siepi et al. 
(2002)(101)  
57 y n 10 Cross 
sectional*  
Single  65 g PUFA: SFA 0.06 6 h TAG and GSH 
 
 
Brachial FMD 
↑TAG at 4 and 6 h (p<0.05) 
↓GSH at 2 h (p<0.05) 
 
↓FMD at 2 h (p<0.05) 
 
15 
 
† Values given per 100 g of test oil of which 41 g was included in the breakfast. 
Arrows refer to the direction of change over time relative to baseline (fasting), unless otherwise stated.  
Abbreviations: AUC; area under the curve, CETP; cholesteryl ester transfer protein, CHO; carbohydrate, E; energy, FMD; flow-mediated dilatation, 
GSH; glutathione, HDL-C; high density lipoprotein cholesterol, IAUC; incremental area under the curve, LDL; low density lipoprotein, Lp (a); 
lipoprotein (a), MaxC; maximum concentration, MUFA; monounsaturated fat, NEFA; non-esterified fatty acid, PoM; postmenopausal women, PrM; 
premenopausal women, PUFA; polyunsaturated fat, RE; Retinyl esters, SFA; saturated fat, TAG; triacylglycerol, TC; total cholesterol.
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Consequences of the decline in oestrogen during the menopause on the lipid profile, 
endothelial function and blood pressure. Adapted from Davis et al.(106)  Abbreviations: ACE; 
angiotensin converting enzyme, AT-1; angiotensin I receptor, COX; cyclooxygenase, eNOS; 
endothelial nitric oxide synthase, HDL-C; high density lipoprotein cholesterol, iNOS; inducible NO 
synthase, LDL-C; low density lipoprotein cholesterol, NO; nitric oxide, PGI; prostaglandin, ROS; 
reactive oxygen species, TAG; Triacylglycerol 
  
Menopause oestrogen decline  
Lipid metabolism   
 Reduced NO-mediated vasodilation via 
inhibition of following processes; 
o eNOS gene expression 
o eNOS phosphorylation which helps to 
increase enzyme activity and correlate 
with increased eNOS activity 
o expression of calmodulin, which is 
necessary for calcium activation of 
eNOS 
 Decreased vasodilator PGI2 production by 
elevating levels of the two key synthetic 
enzymes, COX-1 and PGI2 synthase 
 Increased vascular smooth muscle cell 
proliferation  
 Increased arterial stiffness 
 Increased adhesion of leukocytes 
 Promote expression of adhesion molecules by 
endothelial cells 
 Increased vascular inflammatory response via 
improved induction of vascular inflammatory 
mediators, such as iNOS and COX-2 
 Increased production of ROS 
 Dyslipidaemia in 
fasting state (↑ 
LDL-C and ↓ 
HDL-C) 
 Increased fasting 
and non-fasting 
TAG  
 Insulin resistance  
Activation of renin-
angiotensin system via 
 Increased 
angiotensin II 
production due 
to increased 
AT 1 receptor 
density  
 Increased ACE 
activity 
   
Vascular function   Blood pressure   
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Figure 2: Flow of information through the different phases of the review 
*Of the studies included in the review, one publication reported both postprandial lipaemia and 
vascular function. 
 
 
 
 
Initial search 
(n=1603) 
 
After removal of duplicates  
(n=776) 
  
Relevant articles after 
assessing titles and abstracts  
(n=177) 
 
Potentially eligible articles 
after assessing the full text  
(n=21) 
 
Excluded (n=599) 
 Irrelevant animal 
and human studies 
 in vitro studies 
 No abstracts 
 Reviews   
 Not English 
 
Articles identified 
through hand searching 
(n=2) 
Excluded (n=156) 
 Primary research 
question not 
relevant 
 
Excluded (n=14) 
 Not relevant results  
 
Eligible articles in the review 
(n= 9) describing 7 
independent studies  
 
Studies examining 
postprandial lipaemia (n=9)* 
 
Studies assessing vascular 
function (n=1)* 
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Supplementary Table 1 Acute test meal studies investigating the impact of menopausal status on the variability of the postprandial lipaemic 
responses  
* No comparator group.  
† Values given per 100 g of test oil of which 41 g was included in the breakfast. 
Arrows refer to the direction of change over time compared with premenopausal women.  
Abbreviations: AUC; area under the curve, HDL; high density lipoprotein, IAUC; incremental area under the curve, LDL; low density lipoprotein, Lp 
(a); lipoprotein (a), MaxC; maximum concentration, MUFA; monounsaturated fat, NEFA; non-esterified fatty acid, PoM; postmenopausal women, 
PrM; premenopausal women, PUFA; polyunsaturated fat, SFA; saturated fat, TAG; triacylglycerol, TC; total cholesterol.
Reference Subject group, 
age (mean) and n 
Study 
design 
Meal 
type  
Amount of 
fat (% meal 
fat if 
available) 
Fatty acid  composition Time of 
postprandial 
data 
Postprandial 
measurements 
Significant outcomes  
van Beek et 
al. (1999)(18)  
47-52 y (50 y)  
n 23 PoM women 
and 47-52 y (49 y) 
n 21 PrM women 
Case 
control 
 
Single  50 g (40%) PUFA: SFA 0.06 12 h TAG and 
Vitamin 
A/retinyl 
palmitate  
 
↑TAG AUC at 0-8 h (p=0.024)  
↑TAG ∆AUC (p=0.020) in PoM 
compared to PrM at 0-8 h 
↑Vitamin A AUC (p=0.001) in PoM 
compared to PrM at 0-8 h 
Masding et al. 
(2006)(20)  
34-56 y (42 y) n 8 
PrM and 46-68 y 
(58 y) n 8 PoM 
healthy  
 
32-54 y (39 y) n 8 
PrM and 53-70 y 
(61y) n 8 PoM 
type 2 diabetic 
 
Case and 
control 
Single  45 g No information 6 h TAG, NEFA, 
Glucose, and 
13C-palmitic 
acid 
↑TAG AUC in healthy PoM than PrM 
(p<0.05) 
↑13C-palmitic acid in healthy PoM 
than PrM (p<0.01) 
Schoppen et 
al. (2010)(19)  
18-36 y (20.9 y)  
n 20 PrM and  
51-59 y (55.7 y)  
n 18 PoM 
Case and 
control 
 
 
 
Single  Breakfast: 
75.3 g 
(62.3%) 
 
11.8 %E SFA, 39.7 %E MUFA 
and 6.6 %E PUFA 
7 h TAG and TC  ↑TAG and TC in PoM than PrM 
(p<0.0001) 
Peak TAG at 240 min in PoM and 120 
min PrM (p<0.0001) 
Jackson et 
al.(2010)(21)  
42 y n 37 PrM and 
60 y n 61 PoM 
Case and 
control 
 
Seque
ntial  
Breakfast:  
51 g 
Lunch:  
31 g  
 
29 g SFA at breakfast and 14 g 
SFA at lunch   
8 h TAG ↑TAG IAUC (p=0.002), MaxC 
(p=0.037) and time to reach MaxC 
(p=0.009) in PoM than PrM 
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